SpringWorks Therapeutics, Inc.

NasdaqGS:SWTX Stock Report

Market Cap: US$2.8b

SpringWorks Therapeutics Valuation

Is SWTX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of SWTX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: SWTX ($37.44) is trading above our estimate of fair value ($20.79)

Significantly Below Fair Value: SWTX is trading above our estimate of fair value.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for SWTX?

Key metric: As SWTX is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for SWTX. This is calculated by dividing SWTX's market cap by their current revenue.
What is SWTX's PS Ratio?
PS Ratio20.5x
SalesUS$135.49m
Market CapUS$2.82b

Price to Sales Ratio vs Peers

How does SWTX's PS Ratio compare to its peers?

The above table shows the PS ratio for SWTX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average21.8x
PTGX Protagonist Therapeutics
7.5x-9.3%US$2.3b
TGTX TG Therapeutics
16.9x34.7%US$4.4b
ACLX Arcellx
30.3x22.5%US$4.7b
RYTM Rhythm Pharmaceuticals
32.4x46.1%US$3.7b
SWTX SpringWorks Therapeutics
20.5x44.7%US$2.8b

Price-To-Sales vs Peers: SWTX is good value based on its Price-To-Sales Ratio (20.5x) compared to the peer average (21.8x).


Price to Sales Ratio vs Industry

How does SWTX's PS Ratio compare vs other companies in the US Biotechs Industry?

131 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
3.9x2.4%US$109.25b
BIIB Biogen
2.4x1.3%US$22.65b
MRNA Moderna
2.8x7.2%US$14.35b
INCY Incyte
3.4x8.9%US$13.59b
SWTX 20.5xIndustry Avg. 10.1xNo. of Companies131PS01632486480+
131 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: SWTX is expensive based on its Price-To-Sales Ratio (20.5x) compared to the US Biotechs industry average (10.3x).


Price to Sales Ratio vs Fair Ratio

What is SWTX's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

SWTX PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio20.5x
Fair PS Ratio20.7x

Price-To-Sales vs Fair Ratio: SWTX is good value based on its Price-To-Sales Ratio (20.5x) compared to the estimated Fair Price-To-Sales Ratio (20.7x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst SWTX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$37.44
US$67.33
+79.8%
11.3%US$80.00US$58.00n/a9
Nov ’25US$30.62
US$68.25
+122.9%
11.4%US$80.00US$58.00n/a8
Oct ’25US$32.22
US$68.13
+111.4%
11.6%US$80.00US$58.00n/a8
Sep ’25US$41.71
US$67.63
+62.1%
11.9%US$80.00US$58.00n/a8
Aug ’25US$35.26
US$66.70
+89.2%
10.8%US$80.00US$58.00n/a9
Jul ’25US$38.53
US$65.92
+71.1%
9.9%US$75.00US$58.00n/a9
Jun ’25US$41.46
US$67.36
+62.5%
10.9%US$77.00US$58.00n/a9
May ’25US$46.84
US$67.28
+43.6%
12.3%US$80.00US$55.00n/a8
Apr ’25US$47.62
US$67.78
+42.3%
11.2%US$80.00US$58.00n/a8
Mar ’25US$51.01
US$67.53
+32.4%
10.9%US$80.00US$58.00n/a8
Feb ’25US$44.53
US$57.17
+28.4%
20.8%US$74.00US$45.00n/a6
Jan ’25US$36.50
US$54.83
+50.2%
21.4%US$73.00US$41.00n/a6
Dec ’24US$31.90
US$54.83
+71.9%
21.4%US$73.00US$41.00n/a6
Nov ’24US$23.91
US$50.17
+109.8%
16.5%US$66.00US$41.00US$30.626
Oct ’24US$23.12
US$50.17
+117.0%
16.5%US$66.00US$41.00US$32.226
Sep ’24US$30.33
US$50.17
+65.4%
16.5%US$66.00US$41.00US$41.716
Aug ’24US$29.85
US$57.00
+91.0%
38.6%US$105.00US$41.00US$35.266
Jul ’24US$26.22
US$56.00
+113.6%
40.2%US$105.00US$41.00US$38.536
Jun ’24US$27.69
US$56.00
+102.2%
40.2%US$105.00US$41.00US$41.466
May ’24US$24.01
US$56.33
+134.6%
39.6%US$105.00US$41.00US$46.846
Apr ’24US$25.74
US$58.67
+127.9%
36.3%US$105.00US$45.00US$47.626
Mar ’24US$30.61
US$57.00
+86.2%
33.7%US$99.00US$45.00US$51.016
Feb ’24US$31.88
US$65.33
+104.9%
40.0%US$105.00US$45.00US$44.536
Jan ’24US$26.01
US$64.50
+148.0%
41.6%US$105.00US$40.00US$36.506
Dec ’23US$23.67
US$64.50
+172.5%
41.6%US$105.00US$40.00US$31.906
Nov ’23US$24.26
US$78.20
+222.3%
32.3%US$105.00US$44.00US$23.915

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.


Discover undervalued companies